U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current USFDA approved or emergency use authorized-vaccines
Data published in the prestigious journal ACS Central Science of the American Chemical Society
Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective January 1, 2023
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
It will be the first and only global office for traditional medicine in the world
The company is investing up to US $ 500 million to produce up to 500 million doses each year for the African continent
Confirmed positive phase 3 topline results in addition to Enavogliflozin monotherapy and Metformin combination therapy
he financing was significantly oversubscribed with high demand from both existing and new investors.
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Subscribe To Our Newsletter & Stay Updated
